BioCentury
ARTICLE | Politics & Policy

G-BA head: AMNOG criticisms 'unfounded'

September 5, 2012 1:14 AM UTC

Josef Hecken, chairman of Germany's Federal Joint Committee (G-BA), released an interim analysis of drug benefit assessments under AMNOG and concluded that industry criticism of the pricing law is "unfounded." He noted that G-BA has found at least some degree of additional benefit for 16 of the 25 drugs assessed under the law. Hecken claimed the results are comparable to those from other benefit assessment programs, including those in France, the U.K., Canada and Australia. Hecken added that "the early benefit assessment process has been shown to be transparent, legally sound and predictable for all participants" (see BioCentury, July 16). ...